Company / Financials
AVADEL PHARMACEUTICALS PLC Financials
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$169.1M
FY2024 · +504.8% YoY
Net Income
-$48.8M
FY2024 · +69.5% YoY
Profit Margin
-28.9%
FY2024 · net income / revenue
ROE
-66.1%
FY2024 · return on equity
Total Assets
$164.2M
FY2024
Total Debt
-
FY2024
Equity
$73.8M
FY2024
ROA
-29.7%
FY2024 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$169.1M+504.8% YoYNet Income HistoryProfit after all expenses and taxes-$48.8M+69.5% YoYGross Profit HistoryRevenue minus cost of goods sold$153.8M+467.3% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$15.3M+1705.8% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$42.4M+69.2% YoYSG&A Expense HistorySelling, general, and administrative expenses$181.0M+19.3% YoYR&D Expense HistoryResearch and development spending$15.2M+14.6% YoYInterest Expense HistoryCost of borrowing and debt obligations$10.8M+9.5% YoYIncome Tax HistoryTotal income tax expense-$247.0K+50.7% YoYEPS (Basic) HistoryBasic earnings per share-$0.51+74.5% YoY